Scoring system study for advanced pancreatic cancer
Part of Cancer clinical trials.
This study looks at a scoring system to predict how well people with advanced pancreatic cancer might do after their first chemotherapy. If you have been diagnosed with this type of cancer and are about to start or have just finished your first treatment, this study may be able to use your health information to help guide future care.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You have a confirmed diagnosis of pancreatic ductal adenocarcinoma (a common type of pancreatic cancer)
- You are 18 years or older
- You have not had any other cancer treatment except your first chemotherapy for this cancer
- You have had blood tests (like complete blood count, liver and kidney function, and tumor markers) before starting your first treatment
- You have at least one tumor that can be measured on a scan
- Your daily activity level is good (ECOG score 0 or 1)
- You are expected to live at least 3 more months
- You are not pregnant or breastfeeding
- You agree to join the study and sign a consent form
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This research study looks at how your body's chemistry, immune system, and gut bacteria interact during treatment for advanced pancreatic cancer that cannot be removed by surgery. Researchers will collect blood and stool samples to analyze these factors, hoping to better understand responses to therapy.
This study tracks tiny pieces of cancer DNA in your blood after pancreatic cancer surgery to see if they can predict whether cancer might come back. Researchers will draw blood several times over the next year to test this new monitoring approach.
This Phase 2 trial is for people with pancreatic ductal adenocarcinoma (a type of pancreatic cancer) confirmed by biopsy. It tests a new treatment strategy after the cancer is diagnosed and considers people who haven’t had certain chemotherapy yet.
This trial tests a personalized approach to selecting your first chemotherapy based on tumor gene activity. It aims to match treatment to your cancer’s biology to improve outcomes for people with advanced (metastatic) pancreatic cancer.
This registry collects information about people with advanced pancreatic cancer who are receiving first-line palliative treatment. It helps doctors understand which treatment choices are used and how people do over time.
This study looks at advanced or metastatic pancreatic cancer patients and uses stored tumor tissue to learn what may predict treatment outcomes. You may be able to join if you have had limited prior chemotherapy and can provide an archived tissue sample.
Hear when a new Pancreatic Ductal Adenocarcinoma (PDAC) trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.